This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The post Safety Risk Sinks Cargo Therapeutics Cancer Cell Therapy Prospect, Leading to 50% Staff Cut appeared first on MedCity News. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025.
The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News. Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial.
Sanofi invests €300m in Orano Med's lead-based radioligandsSanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear fuel company Orano.The transaction builds on a three-way partnership between Sanofi, Orano Med, and (..)
When the dust settles, we have a responsibility to turn our shock and grief into fierce determination and lead the charge of responsible, strategic, and sustainable future growth. However, there’s no team better suited to lead that charge than the marketing department. Getting consensus on how to define “qualified leads”.
Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P.
Novo-Catalent Deal, Leading to Another Delay appeared first on MedCity News. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process. The post FTC Seeks More Information on the $16.5B
Rivus Pharmaceuticals’ Series B round will finance ongoing clinical development of its lead drug, a pill that targets mitochondria to increase caloric expenditure.
Those implementing a B2B sales and marketing intelligence solution reported that they have realized 35% more leads in their pipeline and 45% higher-quality leadsleading to higher revenue and growth. However, organizations are fighting back - and winning.
The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.
The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.
Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.
billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. AstraZeneca has committed $1.3 In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
In this eBook, we’ll cover: How you should respond to inbound leads Tactics for engaging outbound leads (cold calls, email automation, and gifts) The key to keeping a prospective account alive for the long haul Buckle up! The art is what you bring to the table—your flair for conversation, your work ethic, your dedication.
Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”
The post INVEST Pitch Perfect Spotlight: How One Startup Aims To Become the Leading Medicaid Mental Health Provider for Kids appeared first on MedCity News. It was recently crowned winner of MedCity News’ INVEST Pitch Perfect contest focused on pediatric mental health.
With Hyrimoz leading the way, sales of the company’s biosimilars reached $623 million in the first three months of this year. . | After spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab).
Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculat | Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of analyst expectations in the third quarter, leading the juggernaut company to reduce (..)
This is your chance to create unprecedented brand awareness, bring in the best leads sales has ever seen, and play an instrumental role in generating new and existing business revenue. Define and agree on “qualified leads”. In this eBook, you’ll discover what it takes to develop and drive a successful marketing-led growth strategy.
The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenreps return to the market. The post GSK Multiple Myeloma Drugs DREAMM Comeback Continues With Phase 3 Data at ASH appeared first on MedCity News.
It provides competitive differentiation, nurtures customer relationships, helps them feel seen and heard , and ultimately leads to increased customer loyalty and repeat business. Always lead with compassion and empathy. The benefits of personalization are without question.
Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study.
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
Leveraging leading industry research from industry analysts, this eBook explores how your sales team can gain back valuable time with the following: Conquering the most difficult pain points in your CRM. Leading integrations that fit directly into your CRM and workflow. The result? Combatting low adoption rates and data quality.
Israel has a powerful tech ecosystem combined with practical government support. The nation’s leaders don’t tell entrepreneurs what to do — but they do provide clarity around the challenges that the healthcare sector is facing, and help gently steer innovation in the right direction.
An Epic Research study found that 16 out of 24 specialties had higher follow-up rates within 90 days of an initial office visit than a telehealth visit.
Read on to learn more about how intent data can save salespeople time -- while capturing more qualified leads in the process! Not only that, but using it will save immense time during your workflow; a win-win on all fronts.
Value-based care depends on keeping a total population of patients healthier and less in need of higher-cost services. To do so, organizations must be able to predict costs in advance, better understand patient risks, and manage the cost of services. Corporate healthcare is set up to do just that.
In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals.
Savvy B2B marketers know that a great account-based marketing (ABM) strategy leads to higher ROI and sustainable growth. In this guide, we’ll cover: What makes for a successful ABM strategy? What are the key elements and capabilities of ABM that can make a real difference? How is AI changing workflows and driving functionality?
Eikon Therapeutics lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.
Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned.
Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.
How AI-powered analytics are leading to more intriguing and satisfying customer interactions. The growing demand among buyers for open marketing platforms that can support “BYOD” (bring your own data).
FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.
Many healthcare workers prefer providing at-home care because it allows them to provide more personal, less hectic care than they can on the hospital floor, said Current Health CEO Chris McGhee.
ObsEva’s uterine fibroids drug linzagolix has hit a snag at the FDA, portending a likely delayed regulatory decision. Rather than stick it out and see if its small molecule can match up against commercialized products from AbbVie and Myovant, ObsEva plans to give up rights to the drug as part of a corporate restructuring.
Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4 billion acquisition of Array Biopharma in 2019.
Nurturing leads through your sales funnel is a daunting task for many business development teams, especially at the scale required to achieve lofty growth goals. But personalized prospecting is possible at scale with the right resources in place. At ZoomInfo, we’ve found that a rock-solid go-to-market playbook is key.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content